Intrapulmonary Pharmacokinetics of MK-7655, a Novel Beta-lactamase Inhibitor, Dosed in Combination with Imipenem/Cilastatin in Healthy Subjects

Trial Profile

Intrapulmonary Pharmacokinetics of MK-7655, a Novel Beta-lactamase Inhibitor, Dosed in Combination with Imipenem/Cilastatin in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Sep 2013

At a glance

  • Drugs Relebactam (Primary) ; Imipenem/cilastatin
  • Indications Gram-negative infections; Pneumonia
  • Focus Pharmacokinetics
  • Most Recent Events

    • 23 Sep 2013 New trial record
    • 12 Sep 2013 Results presented at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top